

Alberto Maria Martelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/94233/publications.pdf>

Version: 2024-02-01

163
papers

14,670
citations

29994

54
h-index

20307

116
g-index

163
all docs

163
docs citations

163
times ranked

26301
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011, 3, 192-222.	1.4	520
3	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. <i>Oncotarget</i> , 2011, 2, 135-164.	0.8	509
4	GSK-3 as potential target for therapeutic intervention in cancer. <i>Oncotarget</i> , 2014, 5, 2881-2911.	0.8	407
5	Nuclear localization and signalling activity of phosphoinositidase C β 2 in Swiss 3T3 cells. <i>Nature</i> , 1992, 358, 242-245.	13.7	329
6	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. <i>Oncotarget</i> , 2012, 3, 1068-1111.	0.8	279
7	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. <i>Oncotarget</i> , 2012, 3, 954-987.	0.8	244
8	Current treatment strategies for inhibiting mTOR in cancer. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 124-135.	4.0	234
9	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. <i>Oncotarget</i> , 2014, 5, 4603-4650.	0.8	231
10	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. <i>Oncotarget</i> , 2010, 1, 89-103.	0.8	227
11	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. <i>Aging</i> , 2017, 9, 1477-1536.	1.4	168
12	The emerging multiple roles of nuclear Akt. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 2168-2178.	1.9	165
13	Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2010, 70, 8097-8107.	0.4	152
14	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. <i>Journal of Cellular Physiology</i> , 2011, 226, 2762-2781.	2.0	147
15	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. <i>Cells</i> , 2020, 9, 1110.	1.8	146
16	Effects of mutations in Wnt/ β -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activityâ€”Diverse effects on cell growth, metabolism and cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2942-2976.	1.9	137
17	Intranuclear 3 β -phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis?. <i>Cellular Signalling</i> , 2006, 18, 1101-1107.	1.7	121
18	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. <i>Advances in Biological Regulation</i> , 2015, 59, 65-81.	1.4	121

#	ARTICLE	IF	CITATIONS
19	Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. <i>Advances in Biological Regulation</i> , 2016, 60, 151-159.	1.4	119
20	Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2009, 69, 3520-3528.	0.4	116
21	The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. <i>Cell Cycle</i> , 2010, 9, 1781-1791.	1.3	110
22	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. <i>Oncotarget</i> , 2012, 3, 371-394.	0.8	109
23	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 991-1002.	1.9	106
24	Changes in nuclear inositol phospholipids induced in intact cells by insulin-like growth factor I. <i>Biochemical and Biophysical Research Communications</i> , 1989, 159, 720-725.	1.0	104
25	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1333-1349.	1.9	104
26	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 449-463.	1.9	104
27	Increase in nuclear phosphatidylinositol 3-kinase activity and phosphatidylinositol (3,4,5) trisphosphate synthesis precede PKC ζ translocation to the nucleus of NGF-treated PC12 cells. <i>FASEB Journal</i> , 1999, 13, 2299-2310.	0.2	103
28	Nuclear Diacylglycerol Produced by Phosphoinositide-specific Phospholipase C Is Responsible for Nuclear Translocation of Protein Kinase C ζ . <i>Journal of Biological Chemistry</i> , 1998, 273, 29738-29744.	1.6	100
29	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. <i>Advances in Biological Regulation</i> , 2015, 57, 75-101.	1.4	100
30	Rapid changes in phospholipid metabolism in the nuclei of Swiss 3T3 cells induced by treatment of the cells with insulin-like growth factor I. <i>Biochemical and Biophysical Research Communications</i> , 1988, 154, 1266-1272.	1.0	99
31	The therapeutic potential of mTOR inhibitors in breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1189-1212.	1.1	93
32	Diacylglycerol kinase ζ is localized in the speckle domains of the nucleus. <i>Experimental Cell Research</i> , 2003, 287, 143-154.	1.2	87
33	The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation. <i>Cancer Research</i> , 2007, 67, 4287-4294.	0.4	87
34	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. <i>Oncotarget</i> , 2017, 8, 14221-14250.	0.8	86
35	Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells. <i>Cancer Research</i> , 2008, 68, 9394-9403.	0.4	84
36	Diverse roles of GSK-3: Tumor promoter/tumor suppressor, target in cancer therapy. <i>Advances in Biological Regulation</i> , 2014, 54, 176-196.	1.4	80

#	ARTICLE	IF	CITATIONS
37	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 438-448.	1.9	79
38	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , 2007, 47, 64-103.	2.9	77
39	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. <i>Cell Cycle</i> , 2011, 10, 3003-3015.	1.3	77
40	Nuclear inositides: facts and perspectives. , 2004, 101, 47-64.		74
41	Autophagy in acute leukemias: A double-edged sword with important therapeutic implications. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 14-26.	1.9	74
42	Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. <i>British Journal of Haematology</i> , 2005, 129, 677-686.	1.2	73
43	Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy. <i>Oncotarget</i> , 2011, 2, 538-550.	0.8	73
44	Nuclear protein kinase C. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 542-551.	1.2	72
45	Phosphoinositide-Phospholipase C $\hat{1}^2$ Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 782-790.	0.8	70
46	Temsirolimus, an mTOR inhibitor, in combination with lower dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML $\hat{1}$ 107). <i>British Journal of Haematology</i> , 2012, 156, 205-212.	1.2	65
47	Drug discovery targeting the mTOR pathway. <i>Clinical Science</i> , 2018, 132, 543-568.	1.8	65
48	Up-regulation of nuclear PLC $\hat{1}$ in myogenic differentiation. <i>Journal of Cellular Physiology</i> , 2003, 195, 446-452.	2.0	61
49	Threonine 308 phosphorylated form of akt translocates to the nucleus of PC12 cells under nerve growth factor stimulation and associates with the nuclear matrix protein nucleolin. <i>Journal of Cellular Physiology</i> , 2003, 196, 79-88.	2.0	61
50	Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. <i>Oncotarget</i> , 2014, 5, 10034-10047.	0.8	60
51	Preclinical testing of the Akt inhibitor triciribine in $\hat{1}$ cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2011, 226, 822-831.	2.0	59
52	The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. <i>Molecular Cancer Research</i> , 2003, 1, 234-46.	1.5	59
53	Selective nuclear translocation of protein kinase C $\hat{1}$ in Swiss 3T3 cells treated with IGF-I, PDGF and EGF. <i>FEBS Letters</i> , 1994, 347, 63-68.	1.3	58
54	Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. <i>Journal of Cellular Physiology</i> , 2005, 202, 623-634.	2.0	58

#	ARTICLE	IF	CITATIONS
55	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. <i>Oncotarget</i> , 2012, 3, 811-823.	0.8	58
56	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. <i>Oncotarget</i> , 2012, 3, 1615-1628.	0.8	54
57	Inositide-Dependent Phospholipase C Signaling Mimics Insulin in Skeletal Muscle Differentiation by Affecting Specific Regions of the Cyclin D3 Promoter. <i>Endocrinology</i> , 2007, 148, 1108-1117.	1.4	53
58	Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118731.	1.9	51
59	Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. <i>Journal of Hematology and Oncology</i> , 2016, 9, 114.	6.9	47
60	Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. <i>Journal of Cellular Physiology</i> , 2006, 207, 836-844.	2.0	45
61	PKR Regulates B56 β -mediated BCL2 Phosphatase Activity in Acute Lymphoblastic Leukemia-derived REH Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 35474-35485.	1.6	45
62	Metformin influences drug sensitivity in pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2018, 68, 13-30.	1.4	45
63	Targeting mTOR in Acute Lymphoblastic Leukemia. <i>Cells</i> , 2019, 8, 190.	1.8	44
64	Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. <i>British Journal of Haematology</i> , 2005, 130, 716-725.	1.2	43
65	Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. <i>Journal of Cellular Physiology</i> , 2004, 200, 291-296.	2.0	42
66	Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology. <i>Advances in Enzyme Regulation</i> , 2009, 49, 2-10.	2.9	42
67	Nuclear diacylglycerol kinase β is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. <i>FASEB Journal</i> , 2007, 21, 3297-3307.	0.2	41
68	Advances in Targeting Signal Transduction Pathways. <i>Oncotarget</i> , 2012, 3, 1505-1521.	0.8	41
69	The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. <i>Cancers</i> , 2010, 2, 1576-1596.	1.7	40
70	Targeting Wnt/ β -catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2020, 235, 5413-5428.	2.0	40
71	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. <i>Advances in Biological Regulation</i> , 2017, 65, 77-88.	1.4	39
72	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF- κ B. <i>Oncotarget</i> , 2016, 7, 1323-1340.	0.8	39

#	ARTICLE	IF	CITATIONS
73	Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118635.	1.9	38
74	The Role Played by Wnt/ β -Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1098.	1.8	38
75	Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry. <i>British Journal of Haematology</i> , 2004, 126, 675-681.	1.2	37
76	Catalytic activity of nuclear PLC- β 1 is required for its signalling function during C2C12 differentiation. <i>Cellular Signalling</i> , 2008, 20, 2013-2021.	1.7	37
77	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 729-742.	1.5	37
78	Nuclear inositol lipid metabolism: More than just second messenger generation?. <i>Journal of Cellular Biochemistry</i> , 2005, 96, 285-292.	1.2	36
79	Tyrosol prevents apoptosis in irradiated keratinocytes. <i>Journal of Dermatological Science</i> , 2015, 80, 61-68.	1.0	36
80	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. <i>Advances in Biological Regulation</i> , 2017, 63, 32-48.	1.4	36
81	Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. <i>Oncotarget</i> , 2014, 5, 7886-7901.	0.8	36
82	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 32089-32103.	0.8	36
83	Antioxidants in the prevention of UVB-induced keratinocyte apoptosis. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2014, 141, 1-9.	1.7	35
84	Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF- κ B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. <i>Advances in Biological Regulation</i> , 2016, 60, 64-87.	1.4	35
85	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update. <i>Journal of Cellular Physiology</i> , 2018, 233, 6440-6454.	2.0	35
86	DGK β under stress conditions: To be nuclear or cytoplasmic, that is the question. <i>Advances in Biological Regulation</i> , 2014, 54, 242-253.	1.4	34
87	Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells. <i>Advances in Biological Regulation</i> , 2014, 56, 6-21.	1.4	34
88	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1878.	1.8	34
89	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2019, 71, 172-182.	1.4	34
90	Nuclear Phosphoinositides: Location, Regulation and Function. <i>Sub-Cellular Biochemistry</i> , 2012, 59, 335-361.	1.0	34

#	ARTICLE	IF	CITATIONS
91	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. <i>Current Pharmaceutical Design</i> , 2016, 22, 2358-2388.	0.9	34
92	Subnuclear localization and differentiation-dependent increased expression of DGK- β in C2C12 mouse myoblasts. <i>Journal of Cellular Physiology</i> , 2006, 209, 370-378.	2.0	33
93	Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia. <i>Molecular Pharmacology</i> , 2008, 74, 884-895.	1.0	33
94	Nuclear phospholipase C β 1 signaling, epigenetics and treatments in MDS. <i>Advances in Biological Regulation</i> , 2013, 53, 2-7.	1.4	32
95	Targeting breast cancer initiating cells: Advances in breast cancer research and therapy. <i>Advances in Biological Regulation</i> , 2014, 56, 81-107.	1.4	32
96	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. <i>Oncotarget</i> , 2015, 6, 10399-10414.	0.8	32
97	Nuclear phosphoinositides and their roles in cell biology and disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2011, 46, 436-457.	2.3	30
98	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. <i>Cell Cycle</i> , 2014, 13, 2237-2247.	1.3	30
99	The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. <i>Cancers</i> , 2019, 11, 629.	1.7	30
100	Cancer therapy and treatments during COVID-19 era. <i>Advances in Biological Regulation</i> , 2020, 77, 100739.	1.4	30
101	The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. <i>Histology and Histopathology</i> , 2010, 25, 669-80.	0.5	30
102	The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. <i>Oncotarget</i> , 2015, 6, 17147-17160.	0.8	30
103	PKR activity is required for acute leukemic cell maintenance and growth: A role for PKR-mediated phosphatase activity to regulate GSK- β phosphorylation. <i>Journal of Cellular Physiology</i> , 2009, 221, 232-241.	2.0	29
104	Cytoplasmic localization of DGK- β exerts a protective effect against p53-mediated cytotoxicity. <i>Journal of Cell Science</i> , 2013, 126, 2785-97.	1.2	29
105	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. <i>Cancers</i> , 2020, 12, 333.	1.7	29
106	Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 1796-1811.	2.0	28
107	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. <i>Advances in Biological Regulation</i> , 2018, 69, 16-34.	1.4	27
108	The Cutting Edge: The Role of mTOR Signaling in Laminopathies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 847.	1.8	27

#	ARTICLE	IF	CITATIONS
109	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 6597-6610.	0.8	27
110	TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase- δ -dependent cell cycle arrest. <i>Cellular Signalling</i> , 2009, 21, 801-809.	1.7	26
111	Identification of a functional nuclear export sequence in diacyl glycerol kinase- δ . <i>Cell Cycle</i> , 2010, 9, 384-388.	1.3	26
112	MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia. <i>Oncotarget</i> , 2014, 5, 120-130.	0.8	26
113	Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. <i>Oncotarget</i> , 2015, 6, 7424-7437.	0.8	25
114	Protective effect of different antioxidant agents in UVB-irradiated keratinocytes. <i>European Journal of Histochemistry</i> , 2017, 61, 2784.	0.6	25
115	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2019, 73, 100633.	1.4	25
116	Diacylglycerol kinase δ is associated with chromatin, but dissociates from condensed chromatin during mitotic phase in NIH3T3 cells. <i>Journal of Cellular Biochemistry</i> , 2008, 105, 756-765.	1.2	24
117	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy. <i>Advances in Biological Regulation</i> , 2012, 52, 214-227.	1.4	23
118	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells – Power of nutraceuticals. <i>Advances in Biological Regulation</i> , 2018, 67, 190-211.	1.4	23
119	Novel 2 α -substituted, 3 α -deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway. <i>British Journal of Haematology</i> , 2004, 126, 574-582.	1.2	22
120	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , 2012, 11, 4447-4461.	1.3	22
121	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. <i>Oncotarget</i> , 2016, 7, 79842-79853.	0.8	22
122	Molecular characterization of the human PLC δ 1 gene. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2002, 1584, 46-54.	1.2	21
123	Roles of p53, NF- κ B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. <i>Advances in Biological Regulation</i> , 2018, 69, 43-62.	1.4	21
124	Erythropoietin (EPO)-induced erythroid differentiation of K562 cells is accompanied by the nuclear translocation of phosphatidylinositol 3-kinase and intranuclear generation of phosphatidylinositol (3,4,5) trisphosphate. <i>Cellular Signalling</i> , 2002, 14, 21-29.	1.7	20
125	Nuclear diacylglycerol kinase- δ is activated in response to nerve growth factor stimulation of PC12 cells. <i>Cellular Signalling</i> , 2004, 16, 1263-1271.	1.7	20
126	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review). <i>International Journal of Oncology</i> , 2014, 45, 909-918.	1.4	20

#	ARTICLE	IF	CITATIONS
127	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 1322-1337.	1.9	20
128	GSK-3: a multifaceted player in acute leukemias. <i>Leukemia</i> , 2021, 35, 1829-1842.	3.3	20
129	DGK1 η is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. <i>Cellular Signalling</i> , 2012, 24, 1573-1582.	1.7	19
130	Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML. <i>Cancers</i> , 2020, 12, 1972.	1.7	19
131	GSK-3 β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. <i>Cells</i> , 2021, 10, 816.	1.8	19
132	Inositide signaling in the nucleus: From physiology to pathology. <i>Advances in Enzyme Regulation</i> , 2010, 50, 2-11.	2.9	17
133	New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. <i>Advances in Biological Regulation</i> , 2019, 74, 100649.	1.4	17
134	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. <i>Oncotarget</i> , 2017, 8, 76525-76557.	0.8	17
135	Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity. <i>Oncotarget</i> , 2011, 2, 109-112.	0.8	17
136	Physiology and pathology of nuclear phospholipase C β 2. <i>Advances in Enzyme Regulation</i> , 2011, 51, 2-12.	2.9	16
137	Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells. <i>Advances in Biological Regulation</i> , 2018, 68, 2-9.	1.4	16
138	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 921-936.	1.5	15
139	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. <i>Aging</i> , 2020, 12, 10194-10210.	1.4	15
140	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. <i>Oncotarget</i> , 2017, 8, 23213-23227.	0.8	15
141	Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. <i>Cells</i> , 2020, 9, 774.	1.8	14
142	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 55690-55703.	0.8	14
143	Novel approaches to target cancer initiating cells-“Eliminating the root of the cancer. <i>Advances in Biological Regulation</i> , 2012, 52, 249-264.	1.4	13
144	Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity. <i>Oncotarget</i> , 2012, 3, 1236-1245.	0.8	13

#	ARTICLE	IF	CITATIONS
145	Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. <i>Cells</i> , 2022, 11, 2155.	1.8	13
146	B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. <i>Cancers</i> , 2020, 12, 3498.	1.7	11
147	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. <i>Advances in Biological Regulation</i> , 2019, 72, 22-40.	1.4	10
148	The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: Implications for therapy of drug resistant breast cancers. <i>Cell Cycle</i> , 2009, 8, 1421-1425.	1.3	9
149	Abilities of 17β -Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2020, 75, 100672.	1.4	9
150	GSK-3 β : A key regulator of breast cancer drug resistance. <i>Cell Cycle</i> , 2014, 13, 697-698.	1.3	8
151	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. <i>Oncotarget</i> , 2017, 8, 113013-113033.	0.8	8
152	Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma. <i>Cell Death and Disease</i> , 2022, 13, 346.	2.7	7
153	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. <i>Advances in Biological Regulation</i> , 2021, 79, 100780.	1.4	6
154	Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. <i>Cells</i> , 2022, 11, 794.	1.8	6
155	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties. <i>Aging</i> , 2022, 14, 3365-3386.	1.4	5
156	Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. <i>Cells</i> , 2022, 11, 1812.	1.8	5
157	Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients. <i>Cell Cycle</i> , 2013, 12, 1815-1816.	1.3	4
158	Regulation of p53 and NF- κ B transactivation activities by DGK α in catalytic activity-dependent and -independent manners. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118953.	1.9	4
159	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. <i>Advances in Biological Regulation</i> , 2021, , 100840.	1.4	4
160	APR-246 "The Mutant TP53 Reactivator" Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells. <i>Biomolecules</i> , 2022, 12, 276.	1.8	4
161	The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine. <i>Pharmaceuticals</i> , 2021, 14, 1325.	1.7	2
162	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1

#	ARTICLE	IF	CITATIONS
163	Cell Communication: Intracellular Pathways – The PI3K/Akt/mTOR Pathway. , 2022, , .		0